Common signs and symptoms of GSM

Article

GSM can be clinically detected in up to 90% of postmenopausal women undergoing evaluation but only one-third report vulvovaginal symptoms when surveyed.

GSM can be clinically detected in up to 90% of postmenopausal women undergoing evaluation. However, only about one-third of menopausal women report vulvovaginal symptoms when surveyed.1 According to the 2010 United States census, there are approximately 50 million women over age 51, the average age of menopause.2,3 That means approximately 17 million women experience GSM symptoms, a number that is likely increasing due to population demographics. Studies have shown that many of these women rate their symptoms as either moderate or severe. Affected women perceive declines in quality of life similar to those of patients with chronic conditions such as arthritis, chronic obstructive pulmonary disease (COPD) and irritable bowel syndrome.4 GMS symptoms also negatively impact sexual satisfaction in over half of patients and strain personal relationships.5

References:

  • Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N, Investigators ES. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286-291.

  • Howden LM, Julia. Age and Sex Composition: 2010. In. Commerce USDo, trans. United States Census Bureau: U.S. Census Bureau; 2010.

  • Avis NE, McKinlay SM. The Massachusetts Women’s Health Study: an epidemiologic investigation of the menopause. J Am Med Womens Assoc (1972). 1995;50(2):45-49, 63.

  • DiBonaventura M, Luo X, Moffatt M, Bushmakin AG, Kumar M, Bobula J. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe. J Womens Health(Larchmt). 2015;24(9):713-722.

  • Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-1799.
Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Navigating vasomotor symptoms in breast cancer patients | Image Credit: menopausefoundationcanada.ca.
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Hot flashes poorly impact sleep quality | Image Credit: intimmedicine.com
How to manage bone health in midlife women | Image Credit: - endocrine.org
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Highlights from The Menopause Society 2023 Annual Meeting  | Image Credit: nursebarb.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.